ScholarIQanswers from OpenAlex

Serum asymmetric dimethylarginine (ADMA) level and cognitive dysfunction in diabetic patients

PaperCitations, authors & open-access status

Serum asymmetric dimethylarginine (ADMA) level and cognitive dysfunction in diabetic patients is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Serum asymmetric dimethylarginine (ADMA) level and cognitive dysfunction in diabetic patients have?

ScholarIQcitation count

Serum asymmetric dimethylarginine (ADMA) level and cognitive dysfunction in diabetic patients has 1 citations in the OpenAlex counts ScholarIQ stores.

When was Serum asymmetric dimethylarginine (ADMA) level and cognitive dysfunction in diabetic patients published?

ScholarIQyear

Serum asymmetric dimethylarginine (ADMA) level and cognitive dysfunction in diabetic patients has 2022 year in the ScholarIQ index.

Open the OpenAlex record →

What is the open-access status of Serum asymmetric dimethylarginine (ADMA) level and cognitive dysfunction in diabetic patients?

ScholarIQoa status

Serum asymmetric dimethylarginine (ADMA) level and cognitive dysfunction in diabetic patients has closed oa status in the ScholarIQ index.

Open the OpenAlex record →

What is the DOI of Serum asymmetric dimethylarginine (ADMA) level and cognitive dysfunction in diabetic patients?

ScholarIQdoi

The DOI for Serum asymmetric dimethylarginine (ADMA) level and cognitive dysfunction in diabetic patients is on the source record.

Open the DOI →

What is the OpenAlex record for Serum asymmetric dimethylarginine (ADMA) level and cognitive dysfunction in diabetic patients?

ScholarIQopenalex

The OpenAlex for Serum asymmetric dimethylarginine (ADMA) level and cognitive dysfunction in diabetic patients is on the source record.

Open the OpenAlex →